Amgen 2023 EPS, revenue estimates within expectations; Lumakras, Evenity see big YoY gains
CharlieAJA

Amgen's 2023 non-GAAP EPS estimate of $17.40 to $18.60, and revenue estimate of $26B to $27.2B both came in within consensus expectations.
Consensus is $18.25 for EPS and $27.07B for revenue.
Estimates do not reflect Amgen's (NASDAQ:AMGN) proposed acquisition of Horizon Therapeutics (HZNP). Both companies received a "Second Request" for information related to the deal from the Federal Trade Commission on Monday.
Although total revenue of $6.8B in Q4 2022 was flat year over year, it was enough to beat analyst expectations. Non-GAAP EPS of $4.09 was in-line.
Sales of Amgen's (AMGN) best selling drug, Enbrel (etanercept), declined 1% compared to the prior-year period to ~$1.1B. 
Medicines that saw the highest YoY percentage growth at, respectively, 58% and 57%, were Lumakras (sotorasib) and Evenity (romosozumab) with $71M and $225M in revenue.
Other therapies that saw double-digit percentage growth in the quarter compared to the prior-year period were Prolia (denomsumab)(14%) $992M; Nplate (romiplostom)(66%) $469M; and Repatha (evolocumab)(22%) $333M.
Amgen ended 2022 with $9.3B in cash and investments, compared to $8B at the end of 2021.
During Q4, there were no stock repurchases made, although 26.1M shares were repurchased in 2022.
Read why Seeking Alpha contributor Clinically Sound Investor recently said Amgen (AMGN) is a buy.